$VRTX News Charting the S&P 500’s slow-motion

New Post Public Reply Private Reply Replies (0) Message Board

Jan 14, 2015 at 10:53 AM

$VRTX News

Charting the S&P 500’s slow-motion breakout 11:00 a.m. Nov. 7, 2014 - Michael Ashbaugh
Twitter gives out 47% of its revenue in stock bonuses 12:51 p.m. Oct. 29, 2014 - Philip van Doorn
11 stocks rising the most as the market heads toward a correction 10:29 a.m. Oct. 15, 2014 - Philip van Doorn
Everything you need to know about investing you learned in grade school 2:09 p.m. Oct. 7, 2014 - Tomi Kilgore
S&P, Nasdaq violate major support 9:02 a.m. Oct. 1, 2014 - Michael Ashbaugh
Bed Bath, Starz gain; Citizens Financial debuts 2:52 p.m. Sept. 24, 2014 - Sue Chang
Oracle falls on earnings, Ellison move; Alibaba soars on debut 3:08 p.m. Sept. 19, 2014 - Sue Chang
Vertex Pharmaceuticals shares jump 4.9%, pace S&P 500 advancers 8:59 a.m. Sept. 5, 2014 - Tomi Kilgore
U.S. stocks push higher; biotechs rally 3:06 p.m. Aug. 13, 2014 - Anora Mahmudova
Vertex leads S&P 500, King drops on outlook 2:55 p.m. Aug. 13, 2014 - Sue Chang
10 stocks suffering the biggest cuts in earnings estimates 12:39 p.m. Aug. 11, 2014 - Philip van Doorn
Kinder Morgan soars, Tesla rallies on upgrade 11:46 a.m. Aug. 11, 2014 - Sue Chang
Mobileye rises for second day; Michael Kors falls 12:23 p.m. Aug. 4, 2014 - Sue Chang
Charting a slow-motion breakout attempt 10:08 a.m. July 23, 2014 - Michael Ashbaugh
U.S. stocks fall; Dow in triple-digit loss 3:36 p.m. June 24, 2014 - Anora Mahmudova
Dow falls over 100 points; energy stocks sell off: Stock market live blog recap 2:46 p.m. June 24, 2014 - blogs.marketwatch.com
Vertex soars on trial success; Best Buy gets buy rating 2:30 p.m. June 24, 2014 - Sue Chang
New studies bode well for Vertex's cystic fibrosis drug, analysts say 12:32 p.m. June 24, 2014 - Russ Britt
Vertex Pharmaceuticals shares skyrocket 50% 8:33 a.m. June 24, 2014 - Sue Chang
Vertex’ late-stage Cystic Fibrosis trial meets goals 6:59 a.m. June 24, 2014 - Anna Prior

Vertex Pharmaceuticals' Kalydeco Remains in Focus in 2015 - Analyst Blog 4:00 p.m. Jan. 12, 2015 - Zacks.com
Digging Deeper: Outperforming Stocks In The Leading Health Care Sector 12:10 p.m. Jan. 12, 2015 - Seeking Alpha
I'm Expecting Some Very Positive News Flow From Gilead 11:55 a.m. Jan. 12, 2015 - Seeking Alpha
Vertex Pharma To Start Next-Gen Cystic Fibrosis Drug Studies Earlier Than Expected 6:08 a.m. Jan. 12, 2015 - TheStreet.com
Gilled Buying Vertex Among Bold Biotech Stock Predictions for 2015 10:42 a.m. Jan. 9, 2015 - TheStreet.com
Top Analyst Upgrades and Downgrades: Crocs, Halliburton, Nuance, Staples, Yelp and More 7:51 a.m. Jan. 9, 2015 - 247WallSt.com
Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1 1:09 p.m. Jan. 8, 2015 - TheStreet.com
Biogen Idec's Critical Nerve Repair Drug is Poised for Big News -- Soon 6:15 a.m. Jan. 8, 2015 - TheStreet.com
Wells Fargo Top Biotech Stocks for 2015 2:10 p.m. Jan. 7, 2015 - 247WallSt.com
Public Shame for Biotechs Not Webcasting 'JPM15' Breakout Sessions 3:08 p.m. Jan. 6, 2015 - TheStreet.com
J.P. Morgan Chimes In With Ratings On BioTech Stocks 11:46 a.m. Jan. 6, 2015 - GuruFocus.com
UPDATE: Barclays Capital Initiates Coverage On Vertex Pharmaceuticals On Leading Position In CF Market 9:24 a.m. Jan. 6, 2015 - benzinga.com
BTIG Initiates Coverage On Vertex Pharmaceuticals, Notes Company's Cystic Fibrosis Therapies 6:11 p.m. Jan. 5, 2015 - benzinga.com
3 Stocks Pushing The Drugs Industry Lower 1:10 p.m. Jan. 5, 2015 - TheStreet.com
Biggest Movers in Healthcare Stocks Now – NLNK ACHN MNKD VRTX 1:30 p.m. Jan. 2, 2015 - InvestorPlace.com
Hottest Healthcare Stocks Now – ACHN MNKD VRTX NLNK 9:45 a.m. Jan. 2, 2015 - InvestorPlace.com
5 Biotech Stocks With Big News Due In January 12:15 p.m. Dec. 31, 2014 - Investors Business Daily
Vertex Pharmaceuticals' Kalydeco Label Expanded in the U.S. - Analyst Blog 4:30 p.m. Dec. 30, 2014 - Zacks.com
3 Biotech Stocks That Soared Past Gilead in 2014 - Analyst Blog 10:41 a.m. Dec. 30, 2014 - Zacks.com
FDA clears expanded label for Kalydeco 3:35 p.m. Dec. 29, 2014 - Seeking Alpha

Technical Scrutiny on Biotech Stocks - Galena Biopharma, Synta Pharma, Merrimack Pharma, Vertex Pharma, and Spectrum Pharma 8:55 a.m. Jan. 7, 2015 - PR Newswire - PRF
Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2014 Financial Results 4:02 p.m. Jan. 6, 2015 - BusinessWire - BZX
On Winning Track: Complementary Research on Vertex, Ignyta, Novartis, Boeing and TransCanada 9:20 a.m. Dec. 30, 2014 - PR Newswire - PRF
U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation 3:11 p.m. Dec. 29, 2014 - BusinessWire - BZX
David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer 9:02 a.m. Dec. 15, 2014 - BusinessWire - BZX
MassMutual Announces the Election of Three Members to its Board of Directors 12:00 p.m. Dec. 10, 2014 - PR Newswire - PRF
Technical Scrutiny on Biotech Stocks - CTI BioPharma, Vertex Pharma, Progenics Pharma, iBio, and NewLink Genetics 8:45 a.m. Dec. 2, 2014 - PR Newswire - PRF
Vertex to Present at Deutsche Bank BioFEST on December 2 4:02 p.m. Nov. 20, 2014 - BusinessWire - BZX
Cystic Fibrosis Foundation Royalty Sale Will Be Transformational for People with CF 9:03 a.m. Nov. 19, 2014 - PR Newswire - PRF
Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation 7:03 a.m. Nov. 5, 2014 - BusinessWire - BZX
Vertex to Present at the Credit Suisse Healthcare Conference on November 11 3:04 p.m. Oct. 30, 2014 - BusinessWire - BZX
Arrival of Former FDA Senior Officials Accelerates Greenleaf Expansion 7:00 a.m. Oct. 29, 2014 - BusinessWire - BZX
Vertex Reports Third Quarter 2014 Financial Results 3:04 p.m. Oct. 28, 2014 - BusinessWire - BZX
Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 8:00 a.m. Oct. 24, 2014 - PR Newswire - PRF
FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation 3:47 p.m. Oct. 21, 2014 - BusinessWire - BZX
Vertex to Announce Third Quarter 2014 Financial Results on October 28 3:01 p.m. Oct. 14, 2014 - BusinessWire - BZX
Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis 8:32 a.m. Oct. 9, 2014 - BusinessWire - BZX
Senior Housing Properties Trust Announces LEED® Gold Certification of the Vertex Pharmaceuticals Biotech Buildings 7:02 a.m. Oct. 8, 2014 - BusinessWire - BZX
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 8:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Analyst Scanner on Biotech Equities - Prana Biotechnology, CytRx, Insmed, Dynavax Technologies, and Vertex Pharma 8:15 a.m. Sept. 11, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...